Maxim Group Upgrades INVO Fertility (NASDAQ:IVF) to “Strong-Buy”

INVO Fertility (NASDAQ:IVF) was upgraded by analysts at Maxim Group from a “hold” rating to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports.

INVO Fertility Trading Down 0.9%

Shares of NASDAQ:IVF opened at $1.10 on Tuesday. INVO Fertility has a twelve month low of $0.71 and a twelve month high of $120.93. The company has a market cap of $2.63 million, a PE ratio of 0.00 and a beta of 2.65. The company’s 50 day moving average is $1.15 and its 200 day moving average is $5.07.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in INVO Fertility stock. Citadel Advisors LLC bought a new stake in shares of INVO Fertility, Inc (NASDAQ:IVF) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned approximately 1.19% of INVO Fertility at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.02% of the company’s stock.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.